Regeneron Pharmaceuticals Files 8-K on Financials

TL;DR

REGN filed an 8-K for financial results, no numbers yet.

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on October 7, 2024, to report on its results of operations and financial condition. The filing does not contain specific financial figures or details about the results of operations, but serves as a notification of these events.

Why It Matters

This filing indicates that Regeneron is providing updates on its financial performance and operational results to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — This is a routine filing to report on financial results, not indicating any immediate adverse events.

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Registrant
• October 7, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select M
• $56 million — ent (" IPR&D ") charge of approximately $56 million on a pre-tax basis. This charge relates
• $0.43 — the third quarter 2024 by approximately $0.43. Acquired IPR&D charges may include IP

Filing Documents

• tm2419098d1_8k.htm (8-K) — 28KB
• 0001104659-24-106432.txt ( ) — 197KB
• regn-20241007.xsd (EX-101.SCH) — 3KB
• regn-20241007_lab.xml (EX-101.LAB) — 33KB
• regn-20241007_pre.xml (EX-101.PRE) — 22KB
• tm2419098d1_8k_htm.xml (XML) — 4KB

02

Item 2.02. Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (" Regeneron " or the " Company ") currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (" GAAP ") and its non-GAAP financial results for the third quarter 2024 will include an acquired in-process research and development (" IPR&D ") charge of approximately $56 million on a pre-tax basis. This charge relates to development milestone and up-front payments in connection with collaboration and licensing agreements. This acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the third quarter 2024 by approximately $0.43. Acquired IPR&D charges may include IPR&D acquired in connection with asset acquisitions as well as up-front, opt-in, certain development milestone payments, and premiums paid on equity securities related to collaboration and licensing agreements. Regeneron does not forecast such acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period. Regeneron's results for the third quarter 2024 have not been finalized and are subject to Regeneron's financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary (unaudited) estimates described herein. The information included in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Note Regarding Forward-Looking Statements This Current Report on Form 8-K (this "Report") includes forward-looking statements that involve risks and uncertainties relating to future events and the fu

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REGENERON PHARMACEUTICALS, INC. /s/ Joseph J. LaRosa Joseph J. LaRosa Executive Vice President, General Counsel and Secretary Date: October 7, 2024

View Full Filing

View this 8-K filing on SEC EDGAR